Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer

KRAS mutations are one of the most common driver mutations in non-small-cell lung cancer (NSCLC) and finding druggable target molecules to inhibit oncogenic KRAS signaling is a significant challenge in NSCLC therapy. We recently identified epiregulin (EREG) as one of several putative transcriptional...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Oncogene
Prif Awduron: Sunaga, N, Kaira, K, Imai, H, Shimizu, K, Nakano, T, Shames, DS, Girard, L, Soh, J, Sato, M, Iwasaki, Y, Ishizuka, T, Gazdar, AF, Minna, JD, Mori, M
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2012
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4451140/
https://ncbi.nlm.nih.gov/pubmed/22964644
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2012.402
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg